285 related articles for article (PubMed ID: 14693068)
1. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
Qian XL; Peng ZL; Liu SL
Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
[TBL] [Abstract][Full Text] [Related]
2. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
3. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
O'Meara AT; Sevin BU
Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
[TBL] [Abstract][Full Text] [Related]
5. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.
Markman M; Blessing JA; DeGeest K; Morgan M; Look KY; Herzog TJ; Rose PG
Gynecol Oncol; 1999 Dec; 75(3):444-6. PubMed ID: 10600304
[TBL] [Abstract][Full Text] [Related]
6. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
7. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
8. [Expression of lung resistant-related protein in ovarian cancer and its clinical significance].
Qian XL; Peng ZL; Liu SL; Wang H; Ni J
Ai Zheng; 2002 Dec; 21(12):1332-4. PubMed ID: 12520742
[TBL] [Abstract][Full Text] [Related]
9. [Phase II clinical study of topotecan hydrochloride in patients with recurrent advanced ovarian cancer].
Li JD; Guan ZZ; Liu JH; Xin XY; Cui Y; Huang CJ; Liu FY; Song L; Bian ML; Zhou QH
Ai Zheng; 2002 Apr; 21(4):416-20. PubMed ID: 12452024
[TBL] [Abstract][Full Text] [Related]
10. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.
Andreotti PE; Cree IA; Kurbacher CM; Hartmann DM; Linder D; Harel G; Gleiberman I; Caruso PA; Ricks SH; Untch M
Cancer Res; 1995 Nov; 55(22):5276-82. PubMed ID: 7585588
[TBL] [Abstract][Full Text] [Related]
12. [Single topotecan or in combination with other chemotherapeutic agents for 18 recurrent advanced ovarian cancer patients].
Li H; Liu L; Zhang W
Zhonghua Zhong Liu Za Zhi; 2001 Nov; 23(6):513-5. PubMed ID: 11859726
[TBL] [Abstract][Full Text] [Related]
13. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
Bookman MA
Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
[TBL] [Abstract][Full Text] [Related]
15. Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.
Tewari KS; Mehta RS; Burger RA; Yu IR; Kyshtoobayeva AS; Monk BJ; Manetta A; Berman ML; Disaia PJ; Fruehauf JP
Gynecol Oncol; 2005 Sep; 98(3):360-8. PubMed ID: 16000215
[TBL] [Abstract][Full Text] [Related]
16. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
17. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
Song J; Shih IeM; Salani R; Chan DW; Zhang Z
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6842-9. PubMed ID: 17982121
[TBL] [Abstract][Full Text] [Related]
18. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
Largillier R; Valenza B; Ferrero JM; Novo C; Creisson A; Lesbats G; Mari V; Hebert C; Chamorey E
Oncology; 2007; 73(3-4):177-84. PubMed ID: 18418010
[TBL] [Abstract][Full Text] [Related]
19. [The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line].
Shi W; Gu M; Liang L
Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):79-82. PubMed ID: 8758798
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
Spannuth WA; Leath CA; Huh WK; Barnes MN; Davidson SA; Kilgore LC; Partridge EE; Austin JM; Alvarez RD
Gynecol Oncol; 2007 Mar; 104(3):591-5. PubMed ID: 17045635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]